Literature DB >> 149657

On the kinetics of the reaction between human antiplasmin and a low-molecular-weight form of plasmin.

B Wiman, L Boman, D Collen.   

Abstract

The reaction between antiplasmin (A) and a low-molecular-weight form of plasmin (P) proceeds in at least two steps: a fast reversible second-order reaction followed by a slower irreversible first-order transition, and may be represented by: P +A k1 in equilibrium k-1 PA k2 leads to PA'. The low-Mr plasmin, which is obtained by limited elastase digestion, is composed of an intact B chain and a small A chain lacking the lysine-binding sites. The k1 of the reaction is (6.5 +/- 0.5) x 10(5) M-1 s-1 which is 30--60 times smaller than that for normal plasmin and antiplasmin. The dissociation constant of the first step is 1.9 x 10(-9) M which is 10 times higher than for normal plasmin and antiplasmin. The rate constant of the second step is (4.2 +/- 0.2) x 10(-3) s-1 for both normal and low-Mr plasmin. Low Mr plasmin which has substrate bound to its active site does not react or reacts only very slowly with antiplasmin. The reaction rate, however, is only slightly influenced by 6-aminohexanoic acid in concentrations up to 1 mM which decrease the reaction rate of normal plasmin approximately 50-fold. The findings further indicate that the lysine-binding site(s) of plasmin are of great importance for the rate of its reaction with antiplasmin.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 149657     DOI: 10.1111/j.1432-1033.1978.tb12360.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  19 in total

1.  Reprogrammed streptokinases develop fibrin-targeting and dissolve blood clots with more potency than tissue plasminogen activator.

Authors:  I Y Sazonova; R A McNamee; A K Houng; S M King; L Hedstrom; G L Reed
Journal:  J Thromb Haemost       Date:  2009-06-30       Impact factor: 5.824

2.  Stopped-flow fluorescence kinetics of bovine alpha 2-antiplasmin inhibition of bovine midiplasmin.

Authors:  S Christensen; L Sottrup-Jensen; U Christensen
Journal:  Biochem J       Date:  1995-01-01       Impact factor: 3.857

3.  alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder.

Authors:  C Kluft; H K Nieuwenhuis; D C Rijken; E Groeneveld; G Wijngaards; W van Berkel; G Dooijewaard; J J Sixma
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

4.  Affinity-chromatographic purification of human alpha 2-antiplasmin.

Authors:  B Wiman
Journal:  Biochem J       Date:  1980-10-01       Impact factor: 3.857

5.  The human alpha(2)-plasmin inhibitor: functional characterization of the unique plasmin(ogen)-binding region.

Authors:  Simon S Gerber; Sofia Lejon; Michael Locher; Johann Schaller
Journal:  Cell Mol Life Sci       Date:  2010-01-29       Impact factor: 9.261

Review 6.  The plasmin-antiplasmin system: structural and functional aspects.

Authors:  Johann Schaller; Simon S Gerber
Journal:  Cell Mol Life Sci       Date:  2010-12-07       Impact factor: 9.261

Review 7.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

8.  The influence of the nature of the asparagine 289-linked oligosaccharide on the activation by urokinase and lysine binding properties of natural and recombinant human plasminogens.

Authors:  D J Davidson; F J Castellino
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

9.  Lipoprotein (a) promotes plasmin inhibition by alpha 2-antiplasmin.

Authors:  J M Edelberg; S V Pizzo
Journal:  Biochem J       Date:  1992-08-15       Impact factor: 3.857

10.  Kinetics of plasmin inhibition in the presence of a synthetic tripeptide substrate. The reaction with pancreatic trypsin inhibitor and two forms of alpha 2-plasmin inhibitor.

Authors:  L C Petersen; I Clemmensen
Journal:  Biochem J       Date:  1981-10-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.